An epigenetic mechanism for capecitabine resistance in mesothelioma

Biochemical and Biophysical Research Communications

Volumn 391, Issue 3, 2010, Pages 1465-1470

  Kosuri, K V ^a   Wu, X ^a   Wang, L ^a   Villalona Calero, M A ^a   Otterson, G A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Capecitabine; Mesothelioma; Methylation; Pemetrexed; Thymidine phosphorylase

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CAPECITABINE; DNA; DOXIFLURIDINE; EXTRACELLULAR GROWTH FACTOR 1; FLUOROURACIL; GROWTH FACTOR; PEMETREXED; PROTEIN HYDROLYSATE; RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN H290; CONTROLLED STUDY; DRUG CYTOTOXICITY; EPIGENETICS; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MESOTHELIOMA; METHYLATION; PERICARDIUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CPG ISLANDS; DEOXYCYTIDINE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FLUOROURACIL; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PERICARDIUM; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; THYMIDINE PHOSPHORYLASE;

EID: 73949117352     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.095     Document Type: Article

References (28)

1. Peto J., Hodgson J.T., Matthews F.E., and Jones J.R. Continuing increase in mesothelioma mortality in Britain. Lancet 345 (1995) 535-539
2. Price B. Analysis of current trends in United States mesothelioma incidence. Am. J. Epidemiol. 145 (1997) 211-218
3. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P.E., and Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience. J. Clin. Oncol. 16 (1998) 145-152
4. Steele J.P. Prognostic factors in mesothelioma. Semin. Oncol. 29 (2002) 36-40
5. Carbone M., and Rdzanek M.A. Pathogenesis of malignant mesothelioma. Clin. Lung Cancer 5 Suppl. 2 (2004) S46-S50
6. Bocchetta M., Di Resta I., Powers A., Fresco R., Tosolini A., Testa J.R., Pass H.I., Rizzo P., and Carbone M. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc. Natl. Acad. Sci. USA 97 (2000) 10214-10219
7. Procopio A., Strizzi L., Vianale G., Betta P., Puntoni R., Fontana V., Tassi G., Gareri F., and Mutti L. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer 29 (2000) 173-179
8. De Luca A., Baldi A., Esposito V., Howard C.M., Bagella L., Rizzo P., Caputi M., Pass H.I., Giordano G.G., Baldi F., Carbone M., and Giordano A. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat. Med. 3 (1997) 913-916
9. Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., Suzuki Y., and Vogelzang N.J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113 (1998) 723-731
10. Baas P., Ardizzoni A., Grossi F., Nackaerts K., Numico G., Van Marck E., van de Vijver M., Monetti F., Smid-Geirnaerdt M.J., van Zandwijk N., Debruyne C., Legrand C., and Giaccone G. The activity of raltitrexed (Tomudex(R)) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur. J. Cancer 39 (2003) 353-357
11. Baas P. Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin. Oncol. 29 (2002) 62-69
12. Steele J.P., O'Doherty C.A., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., and Rudd R.M. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann. Oncol. 12 (2001) 497-499
13. Zidar B.L., Green S., Pierce H.I., Roach R.W., Balcerzak S.P., and Militello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest. New Drugs 6 (1988) 223-226
14. Kindler H.L., Millard F., Herndon II J.E., Vogelzang N.J., Suzuki Y., and Green M.R. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31 (2001) 311-317
15. Bueno R., Appasani K., Mercer H., Lester S., and Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 121 (2001) 225-233
16. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3 (2003) 330-338
17. Curtin N.J., and Hughes A.N. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol. 2 (2001) 298-306
18. Mita A.C., Sweeney C.J., Baker S.D., Goetz A., Hammond L.A., Patnaik A., Tolcher A.W., Villalona-Calero M., Sandler A., Chaudhuri T., Molpus K., Latz J.E., Simms L., Chaudhary A.K., Johnson R.D., Rowinsky E.K., and Takimoto C.H. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J. Clin. Oncol. 24 (2006) 552-562 Epub 2006 Jan 3
19. Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., Burris H., Gatzemeier U., Blatter J., Symanowski J.T., and Rusthoven J.J. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. 21 (2003) 1556-1561
20. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., Gatzemeier U., Boyer M., Emri S., Manegold C., Niyikiza C., and Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21 (2003) 2636-2644
21. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., Legrand C., Bottomley A., Debruyne C., and Giaccone G. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 23 (2005) 6881-6889
22. Nakayama Y., Inoue Y., Nagashima N., Katsuki T., Matsumoto K., Kadowaki K., Shibao K., Tsurudome Y., Hirata K., Sako T., Nagata N., and Itoh H. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. Anticancer Res. 25 (2005) 3755-3761
23. Budman D.R., Meropol N.J., Reigner B., Creaven P.J., Lichtman S.M., Berghorn E., Behr J., Gordon R.J., Osterwalder B., and Griffin T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin. Oncol. 16 (1998) 1795-1802
24. Otterson G.A., Herndon II J.E., Watson D., Green M.R., and Kindler H.L. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer 44 (2004) 251-259
25. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93 (1996) 9821-9826
26. Zhu W.G., Dai Z., Ding H., Srinivasan K., Hall J., Duan W., Villalona-Calero M.A., Plass C., and Otterson G.A. Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene 20 (2001) 7787-7796
27. Zhu W.G., Lakshmanan R.R., Beal M.D., and Otterson G.A. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 61 (2001) 1327-1333
28. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., and Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352 (2005) 997-1003